Bioconversion, Pharmacokinetics, and Therapeutic Mechanisms of Ginsenoside Compound K and Its Analogues for Treating Metabolic Diseases
Current Issues in Molecular Biology · 11.03.2024 · 46 (3) · 2320-2342
DOI: 10.3390/cimb46030148 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 11.03.2024. Verfasst von Md Niaj Morshed und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biopharmaceutical Biotechnology, College of Life Science, Kyung Hee University, Yongin-si 17104, Republic of Korea. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Rare ginsenoside compound K (CK) is an intestinal microbial metabolite with a low natural abundance that is primarily produced by physicochemical processing, side chain modification, or metabolic transformation in the gut. Moreover, CK exhibits potent biological activity compared to primary ginsenosides, which has raised concerns in the field of ginseng research and development, as well as ginsenoside-related dietary supplements and natural products. Ginsenosides Rb1, Rb2, and Rc are generally used as a substrate to generate CK via several bioconversion processes. Current research shows that CK has a wide range of pharmacological actions, including boosting osteogenesis, lipid and glucose metabolism, lipid oxidation, insulin resistance, and anti-inflammatory and anti-apoptosis properties. Further research on the bioavailability and toxicology of CK can advance its medicinal application. The purpose of this review is to lay the groundwork for future clinical studies and the development of CK as a therapy for metabolic disorders. Furthermore, the toxicology and pharmacology of CK are investigated as well in this review. The findings indicate that CK primarily modulates signaling pathways associated with AMPK, SIRT1, PPARs, WNTs, and NF-kB. It also demonstrates a positive therapeutic effect of CK on non-alcoholic fatty liver disease (NAFLD), obesity, hyperlipidemia, diabetes, and its complications, as well as osteoporosis. Additionally, the analogues of CK showed more bioavailability, less toxicity, and more efficacy against disease states. Enhancing bioavailability and regulating hazardous variables are crucial for its use in clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biopharmaceutical Biotechnology, College of Life Science, Kyung Hee University, Yongin-si 17104, Republic of Korea.
- Graduate School of Biotechnology, College of Life Sciences, Kyung Hee University, Yongin-si 17104, Republic of Korea.
ORCID-Profile: Md Niaj Morshed, Md Rezaul Karim, Se Chan Kang, Deok Chun Yang
Zitieren
APA
Morshed, M. N., Akter, R., Karim, M. R., Iqbal, S., Kang, S. C., & Yang, D. C. (2024). Bioconversion, Pharmacokinetics, and Therapeutic Mechanisms of Ginsenoside Compound K and Its Analogues for Treating Metabolic Diseases. Current Issues in Molecular Biology, 46(3), 2320-2342. https://doi.org/10.3390/cimb46030148
Vancouver
Morshed MN, Akter R, Karim MR, Iqbal S, Kang SC, Yang DC. Bioconversion, Pharmacokinetics, and Therapeutic Mechanisms of Ginsenoside Compound K and Its Analogues for Treating Metabolic Diseases. Current Issues in Molecular Biology. 2024;46(3):2320-2342. doi:10.3390/cimb46030148
BibTeX
@article{Morshed2024,
author = {Morshed, Md Niaj and Akter, Reshmi and Karim, Md Rezaul and Iqbal, Safia and Kang, Se Chan and Yang, Deok Chun},
title = {Bioconversion, Pharmacokinetics, and Therapeutic Mechanisms of Ginsenoside Compound K and Its Analogues for Treating Metabolic Diseases},
journal = {Current Issues in Molecular Biology},
year = {2024},
volume = {46},
number = {3},
pages = {2320--2342},
doi = {10.3390/cimb46030148}
}
EUVIMED